Hsbc Holdings PLC Purchases 16,554 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

Hsbc Holdings PLC lifted its position in MaxCyte, Inc. (NASDAQ:MXCT) by 51.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,791 shares of the company’s stock after purchasing an additional 16,554 shares during the quarter. Hsbc Holdings PLC’s holdings in MaxCyte were worth $199,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Barclays PLC lifted its holdings in shares of MaxCyte by 329.3% during the 3rd quarter. Barclays PLC now owns 165,765 shares of the company’s stock worth $645,000 after acquiring an additional 127,156 shares during the period. SG Americas Securities LLC lifted its stake in MaxCyte by 25.9% during the fourth quarter. SG Americas Securities LLC now owns 47,805 shares of the company’s stock worth $199,000 after purchasing an additional 9,836 shares during the period. Gagnon Securities LLC boosted its holdings in MaxCyte by 234.1% during the fourth quarter. Gagnon Securities LLC now owns 197,326 shares of the company’s stock valued at $821,000 after purchasing an additional 138,257 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of MaxCyte by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company’s stock valued at $93,000 after purchasing an additional 2,154 shares during the period. Finally, Chevy Chase Trust Holdings LLC raised its holdings in shares of MaxCyte by 0.6% in the 4th quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company’s stock worth $5,574,000 after buying an additional 7,781 shares in the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Stock Down 2.5 %

MaxCyte stock opened at $2.37 on Friday. MaxCyte, Inc. has a 12-month low of $2.21 and a 12-month high of $5.26. The stock has a 50-day simple moving average of $2.84 and a 200 day simple moving average of $3.62. The stock has a market capitalization of $251.98 million, a price-to-earnings ratio of -6.97 and a beta of 1.38.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). The company had revenue of $10.39 million for the quarter, compared to analyst estimates of $9.05 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. As a group, sell-side analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MXCT. Stifel Nicolaus lowered their price target on MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, March 12th. BTIG Research set a $6.00 target price on shares of MaxCyte and gave the stock a “buy” rating in a report on Wednesday, March 12th.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.